- Spectrum Pharmaceuticals (SPPI) is up 5% in premarket action.
- Out Wednesday morning are what the company calls "encouraging" data from Marqibo and Folotyn studies.
- Results from a Phase 2 study suggest Marqibo could have utility in the treatment of diffuse large B-cell lymphoma" (front-line). Summary: Marqibo substituted for Vincristin in R-CHOP; ORR, 95%; CRR, 90%; 10-year PFS, 64%; 10-year OS, 87%.
- As for Folotyn, data suggest the drug "may provide benefit to patients with early stage peripheral T-cell lymphoma." (PR)
Spectrum Pharma outlines Marqibo, Folotyn studies
Dec 11 2013, 08:42 ET